FLEXION THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT DECEMBER 3, 2012Investor Rights Agreement • August 2nd, 2013 • Flexion Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 3rd day of December, 2012, by and among FLEXION THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
BURLINGTON, MASSACHUSETTS Lease Dated February 22, 2013Burlington Mall Road • August 2nd, 2013 • Flexion Therapeutics Inc • Pharmaceutical preparations • Massachusetts
THIS INSTRUMENT IS AN INDENTURE OF LEASE in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in a certain building (the “Building”) known as, and with an address at, 10 Burlington Mall Road, Burlington, Massachusetts 01803.
December 3, 2012 AstraZeneca AB SE-431 83 Mölndal Sweden Re: Out-License Agreement by and between AstraZeneca AB (“AstraZeneca”) and Flexion Therapeutics AG (“Flexion”) effective June 12, 2009 (the “Agreement”) Dear Sirs,Flexion Therapeutics Inc • August 2nd, 2013 • Pharmaceutical preparations
This letter sets forth our mutual understanding and certain amendments to the Agreement with respect to Licensed Products and Compounds (the compound known as FX005 ([…***…])). Capitalized terms used herein and not otherwise defined shall be given the meaning in the Agreement. In consideration of the rights and covenants of the Parties the sufficiency of which is acknowledged, Flexion and AstraZeneca agree as follows:
